综合介入治疗原发性肝癌对提高患者生存率的临床价值分析

Study on the Clincal Value of Comprehensice Interventional Therapy in Increasing Survival Rate of Primary Liver Cancer

目的综合介入治疗原发性肝癌对提高患者生存率的临床价值进行分析探讨。方法将我院2012年1月—2014年12月收治的70例原发性肝癌患者随机分为两组,对照组35例患者行单纯经导管肝动脉化疗栓塞术治疗,观察组35例患者行综合介入治疗,对比两组患者的治疗效果及生存率。结果观察组治疗有效率为88.6%,明显高于对照组的77.1%(P<0.05),观察组术后半年生存率为97.14%,1年生存率为80.00%,2年生存率为57.14%,明显高于对照组的88.57%、57.14%、45.71%(P<0.05)。结论对原发性肝癌患者采用综合介入治疗,可有效提高治疗效果,减缓肿瘤发展速度,缩小肿瘤,提高患者的生存率,有较高的临床应用价值。

Objective To study the clincal value of comprehensice interventional therapy in increasing survival rate of primary liver cancer. Methods 70 cases with primary liver cancer in our hospital from January 2012 to December 2014 were randomly divided into control group and experimental group, 35 cases in control group were treated by transcatheter portal vein embolization, 35 cases in experimental group were treated by comprehensice interventional therapy, the survival rate of the two groups were compared. Results The effective rate of experimental group was 88.6%, which was much higher than that of control group of 77.1%（P〈0.05）. The six-month survival rate of experimental group was 97.14%, oneyear survival rate was 80.00%, two-year survival rate was 57.14%, which was much higher than that of control group of 88.57%, 57.14%,45.71%（P〈0.05）. Conclusion Adopting comprehensice interventional therapy in primary liver cancer can increase survival rate, retard the tumor development, shrink tumor volume, is worthy of clincal application.